Gain Therapeutics shares are trading higher after Oppenheimer issued an Outperform rating on the stock and announced a price target of $8.
Portfolio Pulse from Benzinga Newsdesk
Gain Therapeutics shares are trading higher after Oppenheimer issued an Outperform rating on the stock and announced a price target of $8.
August 14, 2024 | 7:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gain Therapeutics shares are trading higher following an Outperform rating and an $8 price target from Oppenheimer.
The Outperform rating and the $8 price target from Oppenheimer are likely to boost investor confidence and drive short-term price appreciation for Gain Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100